Madiha Derouazi
Direttore Tecnico/Scientifico/R&S presso AC IMMUNE SA
Patrimonio netto: 7 271 $ in data 30/04/2024
Profilo
Madiha Derouazi is the founder and current Chief Executive Officer & Director of Amal Therapeutics SA, which is founded in 2012.
She is also currently the Chief Scientific Officer at AC Immune SA, where she started in 2024.
Dr. Derouazi has a graduate degree from the Technical University of Berlin and a doctorate degree from the Swiss Federal Institute of Technology.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
AC IMMUNE SA
0.00% | 01/03/2024 | 3 175 ( 0.00% ) | 7 271 $ | 30/04/2024 |
Posizioni attive di Madiha Derouazi
| Società | Posizione | Inizio |
|---|---|---|
| AC IMMUNE SA | Direttore Tecnico/Scientifico/R&S | 01/01/2024 |
Amal Therapeutics SA
 Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Fondatore | 03/09/2012 |
Precedenti posizioni note di Madiha Derouazi
| Società | Posizione | Fine |
|---|
Formazione di Madiha Derouazi
| Technical University of Berlin | Graduate Degree |
| Swiss Federal Institute of Technology | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| AC IMMUNE SA | Health Technology |
| Aziende private | 1 |
|---|---|
Amal Therapeutics SA
Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Madiha Derouazi